OCTO-TELEMATICS
OCTO today announced it has launched OCTO IoT4Insurance on Salesforce AppExchange, empowering customers to determine individual Policyholder driving behavior that favors their engagement and cross-selling. Insurance marketing and sales teams can build campaigns selecting the target from their portfolio in order to propose a motor line personalized offer based on OCTO scoring.
Built on the Salesforce Platform, OCTO IoT4Insurance is currently available on the AppExchange at OCTO IoT4Insurance
OCTO IoT4Insurance
Octo IoT4Insurance revolutionises the insurance experience selecting and qualifying leads, increasing motor’s portfolio quality and profitability. Thanks to the OCTO IoT4Insurance app and Salesforce platform, insurers now have a unique and clear 360°view of the policyholder.
OCTO’s goal is to increase customer-perceived value and to support lead generation and fast-growing new opportunities.
Nicola Veratelli, OCTO Group CEO said: “ We are very pleased to be working with Salesforce to achieve our process improvement goal of enabling our insurance partners to operate more efficiently and realise better financial results. We will continue to innovate in the insurance sector, providing effective and valuable solutions for our partners.”
“OCTO IoT4Insurance is a welcome addition to AppExchange, as they power digital transformation for customers with a clear view of customers for insurance companies." said Woodson Martin, GM of Salesforce AppExchange. "AppExchange is constantly evolving to enable our partners to build cutting-edge solutions to drive customer success."
About Salesforce AppExchange
Salesforce AppExchange, the world’s leading enterprise cloud marketplace, empowers companies to sell, service, market and engage in entirely new ways. With more than 6,000 solutions, 8 million customer installs and 90,000 peer reviews, it is the most comprehensive source of cloud, mobile, social, IoT, analytics and artificial intelligence technologies for businesses.
Additional Resources
- Like Salesforce on Facebook:http://www.facebook.com/salesforce
- Follow Salesforce on Twitter: https://twitter.com/salesforce
- Become a fan of OCTO: https://www.facebook.com/octotelematicsitalia/ and https://www.facebook.com/octotelematics/
- Follow OCTO on Twitter: https://twitter.com/OctoTelematics
Salesforce, AppExchange and others are among the trademarks of salesforce.com, Inc.
About OCTO
Founded in 2002, OCTO is a leading provider of telematic services and advanced data analytics for the Insurance sector, and increasingly one of the leading companies offering solutions for Fleet Telematics and Smart Mobility. With OCTO’s unique propositions already established in the field of Insurtech and Smart Mobility, OCTO continues to expand in new sectors and international markets. In the context of an increasingly connected world, OCTO’s advanced analytics and its set of IoT Big Data, generates actionable analytics giving life to a new era of Smart Telematics. Today it has over 6 million connected users and the largest database of vehicle telematics data in the world, with over 280 billion miles of driving data collected and 480,000 claims and insurance events analysed. It also manages over 400,000 vehicle rentals per month.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005499/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom